What is Genprex, Inc. (GNPX) stock price today?

Genprex, Inc. (GNPX) is currently trading at $2.72, down 1.09% today.

What is GNPX P/E ratio?

Genprex, Inc.'s P/E ratio is -0.02. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is GNPX return on equity (ROE)?

Genprex, Inc.'s return on equity (ROE) is -163.13%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Genprex, Inc.'s market cap?

Genprex, Inc. has a market capitalization of $1.37M.

NASDAQ · Biotechnology

Genprex, Inc. (GNPX) Stock

$2.72 -1.09% NASDAQ: GNPX Healthcare

Valuation

Metric	Value
Price	$2.72
Market Cap	$1.37M
P/E Ratio	-0.02
P/B Ratio	0.09
P/S Ratio	0.00
EPS (TTM)	$-17.40
52-Week High	$1210.00
52-Week Low	$2.53
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-163.13%
ROA	-96.27%
ROCE	-107.08%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	4.00

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-21.0M	$-24.0M	$-31.0M	$-21.0M	$-16.0M
Net Profit	$-21.0M	$-24.0M	$-31.0M	$-21.0M	$-16.0M
EPS	$-19305.00	$-21780.00	$-24816.00	$-5872.98	$-382.80
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$43.0M	$25.0M	$11.0M	$4.0M	$10.0M
Total Liabilities	$2.0M	$3.0M	$3.0M	$3.0M	$2.0M
Cash	$39.0M	$21.0M	$7.0M	$2.0M	$8.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

Genprex’s Reqorsa combo secures Canadian patent for lung cancer Pharmaceutical Technology · Jun 23, 2026 Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer PR Newswire · Jun 22, 2026 Genprex to Participate at BIO International Convention 2026 PR Newswire · Jun 17, 2026 Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting PR Newswire · May 26, 2026 Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting PR Newswire · May 14, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-14.0M	$-18.0M	$-25.0M	$-17.0M	$-15.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$277.0M	$0
Net Cash Flow	$11.0M	$-18.0M	$-14.0M	$-5.0M	$6.0M
Free Cash Flow	$-14.0M	$-18.0M	$-25.0M	$-17.0M	$-15.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	0.87
FCF Yield	-1108.68%
Quick Ratio	6.77
Interest Coverage	-34.78
Return 1Y	-96.69%
Return 3Y	-99.97%
Return 5Y	-99.99%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BDRXBiodexa Pharmaceuticals Plc	$1.71	-3.39%	0.00	$1.28M	0.00%
BIVIBioVie Inc.	$1.39	+8.59%	-0.46	$10.48M	0.00%
CEROCERo Therapeutics Holdings, Inc.	$0.01	-7.69%	0.00	$14464	0.00%
CMMBChemomab Therapeutics Ltd.	$1.43	-2.72%	-1.30	$8.80M	0.00%
CNSPCNS Pharmaceuticals, Inc.	$5.35	+0.00%	-0.23	$7.82M	0.00%

About Genprex, Inc.

Genprex, Inc. is led by CEO Ryan Confer, employs 15 people, headquartered in US, publicly traded since 2018.

Genprex, Inc. (GNPX) stock trades at $2.72 with a market capitalization of $1.37M. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of 0.09, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.53 and $1210.00, and currently trades 99.8% below its 52-week high.

On profitability, Genprex, Inc. generates a return on equity (ROE) of -163.13%, return on capital employed of -107.08%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides